Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.7126 USD | +1.80% |
|
-9.56% | -77.87% |
18/06 | Oppenheimer Downgrades Ovid Therapeutics to Market Perform | MT |
18/06 | B. Riley Adjusts Price Target on Ovid Therapeutics to $3 From $9, Maintains Buy Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-77.87% | 50.56M | |
+16.49% | 122B | |
+21.73% | 115B | |
+22.18% | 26.64B | |
-21.81% | 19.91B | |
-16.89% | 16.32B | |
-18.81% | 15.49B | |
-44.74% | 15.52B | |
+62.72% | 14.83B | |
+3.09% | 13.67B |
- Stock Market
- Equities
- OVID Stock
- News Ovid Therapeutics Inc.
- BTIG Adjusts Price Target on Ovid Therapeutics to $5 From $11, Maintains Buy Rating